Halozyme Therapeutics
Halozyme Therapeutics

Halozyme Therapeutics

Biotechnology
WebsiteInvestor RelationsSEC
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

$12.1B

Market Cap • 9/10/2026

1998

(28 years)

Founded

2004

(22 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

84,6

P/S

7,3

P/EBITDA

17,1

P/OCF

14,8

P/FCF

15,1

P/E

31,9

BVPS

1,2

EPS

3,4

Market Cap

Market Cap

12,1B

EV

14,1B

EV/Revenue

8,5

EV/EBITDA

19,7

EV/EBIT

23,5

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

2,9%

Total Yield

2,9%

Payout

0%

Retained Earnings

151,3M

Profitability

Gross Margin

82,4%

EBITDA Margin

42,8%

EBIT Margin

35,9%

Net Margin

24,9%

D&A/EBITDA

14,1%

R&D/Revenue

6,2%

Capex/Revenue

0,7%

Capex/D&A

10,8%

Capex/OCF

1,5%

SBC/OCF

7,7%

% PPE

3,3%

% Goodwill

22,6%

ROE

173,7%

ROIC

19,2%

Growth

CAGR Revenue 5Y

32,2%

CAGR Op. Income 5Y

17,9%

CAGR Net Income 5Y

12,6%

CAGR EPS 5Y

16,5%

CAGR OCF 5Y

40%

Leverage

N.D./EBITDA

2,7

Debt/Equity

0%

Current Ratio

2,7

Quick Ratio

2

Interest Coverage

2941,4%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium